Literature DB >> 17200160

The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands.

M E Rodriguez1, Y Almaden, S Cañadillas, A Canalejo, E Siendones, I Lopez, E Aguilera-Tejero, D Martin, M Rodriguez.   

Abstract

We previously demonstrated that extracellular calcium regulates vitamin D receptor (VDR) expression by parathyroid cells. Since the calcimimetic R-568 potentiates the effects of calcium on the calcium-sensing receptor, it was hypothesized that administration of R-568 may result in increased VDR expression in parathyroid tissue. In vitro studies of the effect of R-568 on VDR mRNA and protein were conducted in cultures of whole rat parathyroid glands and human hyperplastic parathyroid glands. In vivo studies in Wistar rats examined the effect of R-568 and calcitriol alone and in combination. Incubation of rat parathyroid glands in vitro with R-568 (0.001-1 microM) resulted in a dose-dependent decrease in parathyroid hormone (PTH) secretion and an increase in VDR expression (mean +/- SE). Incubation in 1 mM calcium + 0.001 microM R-568 elicited an increase in VDR mRNA (306 +/- 46%) similar to the maximum increase detected with 1.5 mM calcium (330 +/- 42%). In vivo, VDR mRNA was increased after administration of R-568 (168 +/- 9%, P < 0.001 vs. control) or calcitriol (198 +/- 16%, P < 0.001 vs. control). Treatment with R-568 also increased VDR protein in normal rat parathyroid glands and in human parathyroid glands with diffuse, but not nodular, hyperplasia. In conclusion, the present study shows that the calcimimetic R-568 exerts a stimulatory effect on VDR expression in the parathyroid glands of study models and provides additional evidence for the use of calcimimetics in the treatment of secondary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17200160     DOI: 10.1152/ajprenal.00262.2006

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  18 in total

Review 1.  New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.

Authors:  Jorge B Cannata-Andía; Minerva Rodriguez-García; Pablo Román-García; Diego Tuñón-le Poultel; Francisco López-Hernández; Diego Rodríguez-Puyol
Journal:  Pediatr Nephrol       Date:  2010-02-12       Impact factor: 3.714

2.  Effect of cinacalcet cessation on hyperparathyroidism in kidney transcaplant patients after long-term dialysis therapy.

Authors:  Kentaro Nakai; Hideki Fujii; Mikiko Yoshikawa; Keiji Kono; Yuriko Yonekura; Shunsuke Goto; Takeshi Ishimura; Masashi Takeda; Masato Fujisawa; Shinichi Nishi
Journal:  Clin Exp Nephrol       Date:  2015-03-18       Impact factor: 2.801

3.  Case report: Electron microscopic evaluation of bone from a patient treated with cinacalcet hydrochloride, maxacalcitol, and alfacalcidol for hyperparathyroid bone disease with secondary hyperparathyroidism.

Authors:  A Yajima; K Tsuchiya; L F Bonewald; M Inaba; Y Tominaga; T Tanizawa; A Ito; K Nitta
Journal:  Osteoporos Int       Date:  2018-02-28       Impact factor: 4.507

4.  Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study.

Authors:  Emanuel Zitt; Christine Jäger; Alexander R Rosenkranz; Manfred Eigner; Katharina Kodras; Josef Kovarik; Helmut Graf; Frank Pétavy; Sabine Horn; Bruno Watschinger
Journal:  Wien Klin Wochenschr       Date:  2011-01-21       Impact factor: 1.704

5.  The parathyroid is a target organ for FGF23 in rats.

Authors:  Iddo Z Ben-Dov; Hillel Galitzer; Vardit Lavi-Moshayoff; Regina Goetz; Makoto Kuro-o; Moosa Mohammadi; Roy Sirkis; Tally Naveh-Many; Justin Silver
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

6.  Vitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity.

Authors:  Songcang Chen; Christopher S Law; David G Gardner
Journal:  J Steroid Biochem Mol Biol       Date:  2009-12-02       Impact factor: 4.292

Review 7.  Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.

Authors:  Jordi Bover; Pablo Ureña; César Ruiz-García; Iara daSilva; Patricia Lescano; Jacqueline del Carpio; José Ballarín; Mario Cozzolino
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-29       Impact factor: 8.237

8.  Molecular and morphological approach of uremia-induced hyperplastic parathyroid gland following direct maxacalcitol injection.

Authors:  Kazuhiro Shiizaki; Ikuji Hatamura; Eiko Nakazawa; Manabu Ogura; Takahiro Masuda; Tadao Akizawa; Eiji Kusano
Journal:  Med Mol Morphol       Date:  2008-07-01       Impact factor: 2.309

9.  The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats.

Authors:  Charles Henley; James Davis; Gerald Miller; Edward Shatzen; Russ Cattley; Xiaodong Li; David Martin; Wei Yao; Nancy Lane; Victoria Shalhoub
Journal:  Eur J Pharmacol       Date:  2009-05-24       Impact factor: 4.432

10.  The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion.

Authors:  Lakshmi Kantham; Steven J Quinn; Ogo I Egbuna; Khanjan Baxi; Robert Butters; Jian L Pang; Martin R Pollak; David Goltzman; Edward M Brown
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-10       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.